
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience has shown promising advancements in its clinical-stage assets, particularly with ALTO-207 (CTC-501), which has achieved consistent high dosing and rapid titration, leading to enhanced tolerability compared to current treatment options, thereby positively impacting treatment outcomes for depressive symptoms. Financially, the company's revenue for FY24 has reached $1.08 billion, a substantial increase of approximately 60% from FY23, indicating strong market demand and effective product performance. Additionally, the introduction of a new transdermal formulation for ALTO-101 that improves safety and pharmacokinetics supports ongoing studies, reinforcing the potential growth and innovation in its precision psychiatry pipeline.
Bears say
Alto Neuroscience Inc's stock has faced persistent pressure since its IPO in 2024, primarily due to the significant failure of its lead asset, ALTO-100, in a pivotal Phase 2b study for major depressive disorder (MDD) in October 2024, compounded by negative results from ALTO-300. This setback raises concerns over the company's ability to effectively target patients with challenging cognitive issues, which could lead to heightened treatment resistance and diminished prospects for successful outcomes. Additionally, the ongoing Phase 2b study in bipolar depression, while a potential avenue for recovery, presents considerable risks with a low probability of success given the company's history of disappointing readouts and the complexities associated with neuroplasticity deficits.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares